AstraZeneca (NASDAQ: AZN): Navigating Cancer Drug Pipeline Setbacks with Strong Growth Prospects

• AstraZeneca (NASDAQ: AZN) received an "Outperform" rating from CICC, highlighting its investment potential despite recent pipeline challenges.
• The company faced a setback with the discontinuation of its volrustomig trial for non-small cell lung cancer (NSCLC), underscoring the inherent risks in drug development.
• Positive clinical trial results for drugs like Tagrisso and Enhertu in cancer treatments reinforce AstraZeneca's strong growth prospects and pharmaceutical sector leadership.

On August 23, 2026, investment firm CICC initiated coverage on AstraZeneca (NASDAQ: AZN), giving it an "Outperform" rating when the stock was priced at $165.98. AstraZeneca is a global pharmaceutical company that discovers, develops, and sells prescription medicines. It is a major player in treating diseases like cancer, where it competes with firms like Merck (NYSE: MRK).

The company recently faced a setback in its drug development pipeline. As highlighted by Zacks Investment Research, AstraZeneca discontinued its phase III study for the drug volrustomig in non-small cell lung cancer (NSCLC). An independent review concluded the drug was unlikely to meet its primary survival goals for patients.

Despite this, other areas of the company's cancer drug pipeline show strong results. As reported by Proactive Investors, the investment bank Citigroup (NYSE: C) maintained its 'buy' rating on AstraZeneca. Citigroup believes AstraZeneca continues to offer the strongest growth and drug development profile in the pharmaceutical sector.

This positive outlook is supported by recent clinical trial successes. As highlighted by Business Wire, the Phase III SAFFRON trial showed that its drug Tagrisso, combined with another drug, significantly improved survival in patients with a specific type of lung cancer. Citigroup projects this could generate approximately US$500 million in peak sales.

Additionally, another study called DESTINY-Lung04 also met its main goal. This trial evaluated the drug Enhertu as a first-line treatment for a different type of NSCLC. These positive developments in its late-stage pipeline provide a stronger outlook for the company's future growth in cancer treatments.